Introduction
============

Gastric cancer (GC) is one of the most common malignant tumours and its mortality rate ranks third worldwide. As a result of national screening plans and improvements in chemotherapy, the mortality has significantly declined. However, the mortality rate of GC is relatively higher in developing countries than in developed countries[@B1]. With the accumulation of genetic mutations and epigenetic changes, the morbidity of GC could be higher[@B2]. In recent years, traditional chemotherapy and molecular target therapy have made great progress, but their efficacy in advanced stages of GC is still limited. Therefore, there is a pressing need to identify novel potential treatment targets.

Rab GTPases are members of the Ras GTPase superfamily, which regulate membrane identity and vesicle trafficking processes by switching cycles between the GDP- and GTP-bound states[@B3]. Previous studies have shown that RABs play an important role in epithelial cell transformation and motility of cancer cells. The guanine nucleotide exchange factors (GEFs) promote the expression of Rab proteins, which would boost GDP release by regulating specific residues in the switch regions of Rabs[@B4]. RAB3A-interacting protein (Rab3IP) is a Rab-specific GEF and a major activator of Rab proteins, which is directly regulated by Rab11[@B5]. Previous studies by de Bruijn *et a*l.[@B6] have confirmed that Rab3IP interacts with SSX2, a cancer-related protein, in Hela cells. In addition, several studies have revealed that Rab3IP might play an important role in malignant cellular growth, as it was found to be upregulated, and is considered a tumour-specific marker in some malignant tumours such as colorectal cancer, major salivary carcinomas, and glioma[@B7]-[@B9]. In our previous study, we also found that, Rab3IP is upregulated in both gastric cancer cell lines and human tissues, and interacts with SSX2. Furthermore, we also revealed the involvement of Rab3IP and SSX2 in the epithelial-mesenchymal transition (EMT) and their potential implication in the invasion and metastasis of gastric cancer[@B10]. However, the potential function of Rab3IP during the proliferation of GC cells have not been totally revealed.

MicroRNAs (miRNAs) are a class of small-regulatory RNA molecules of \~22 nt in length that induce the inhibition of protein translation through binding to the 3ʹ untranslated regions (UTRs) of target mRNAs and causing their degradation [@B11], [@B12]. Emerging evidences about the expression profile and function of miRNAs have proved their essential role in cellular differentiation, proliferation, and apoptosis in human cancer. Moreover, a series of miRNAs has been found to contribute to the cell cycle and apoptosis regulation in GC[@B13]. Nevertheless, the role and underlying mechanism of miRNAs in the regulation of Rab3IP-specific GEF associated with GC remains elusive and further investigation is required[@B14].

In this study, we investigated the expression pattern and possible function of Rab3IP in proliferation and tumorigenicity of GC cells. Furthermore, we studied the involvement of Rab3IP in cell autophagy, which is supposed to be highly associated with the cell proliferation process of GC. Meanwhile, we also identified miR-532-3p as the miRNA that targets Rab3IP and illustrate its potential regulatory mechanism.

Materials and Methods
=====================

Tumour tissue specimens
-----------------------

Paired samples of GC and normal mucosal tissues were obtained from 150 patients who underwent standard gastrectomy at Nanfang Hospital of Southern Medical University from 2009 to 2014. Histological diagnosis, and pathological and clinical materials were evaluated and provided by the Department of Pathology and Department of General Surgery in Nanfang Hospital, according to the 8^th^ version of American Joint Committee on Cancer (AJCC) stage guidelines. The Ethics Committee of Nanfang Hospital of Southern Medical University approved this study in compliance with the Declaration of Helsinki.

Cell culture and transfection
-----------------------------

GC cell lines, including AGS, MKN45, BGC823, SGC7901, MGC803, and MKN28, and normal gastric mucosa cells (GES-1), were obtained from Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI 1640 mixed with 10% foetal bovine serum under 5% CO~2~ at 37 ºC. Plasmids containing Rab3IP cDNA (the sequence results are shown in **[Supplementary materials](#SM0){ref-type="supplementary-material"}**) and Rab3IP-specific siRNAs (5\'CCAGTGGGATTACAACCTA3\') were purchased from OBIO Biotechnology Company (Shanghai, China). Rab3IP-knockdown lentiviruses were obtained from GeneChem Company (Shanghai, China) and were used to establish the Rab3IP-knockdown cell lines, namely AGS-Rab3IP (-) cells. Rab3IP overexpressing lentiviruses were also from GeneChem Company (Shanghai, China) and were used to generate the Rab3IP-overexpression cell lines, namely MKN45-Rab3IP (+) cells. Negative control cell lines were also established, called AGS-Rab3IP (-)-NC and MKN45-Rab3IP (+)-NC cells. The miR-450-5p, miR-217, miR-532-3p, miR-935, and miR-584-5p mimics as well as the negative control were purchased from OBIO Biotechnology Company (Shanghai, China) and transfected into GC cells, using the Lipofectamine 2000 Transfection Reagent (Thermo Fisher, USA).

Total RNA extraction, cDNA synthesis, and quantitative real-time PCR (qRT-PCR)
------------------------------------------------------------------------------

Total RNA was isolated from cells or tissues, using RNAiso Plus reagent (Takara, Tokyo, Japan) according to the manufacturer\'s instructions. The concentration and quality of the RNA were measured by UV absorbance at 260 and 280 nm (260/280 nm) using the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). cDNA was then synthesised using the PrimScript ^TM^ RT Reagent Kit(Takara, Japan). qRT-PCR was performed using the SYBR Premix Ex Taq II Kit (Takara, Japan) to assess gene expression. Data were normalised to the geometric mean of the expression of the housekeeping gene *GAPDH*, and relative expression was calculated using the 2^-ΔΔCT^ method.

Western blotting
----------------

Total proteins were collected from cells or tissues, using a PIPA lysis buffer (Biouniquer Technology, Nanjing, China) according to the manufacturer\'s instructions. Protein concentration was measured at 562 nm using the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). SDS-PAGE was used to separate equal amounts of protein lysates from fresh tissues or cells. Proteins were transferred onto PVDF membranes, which was followed with western blotting according to standard methods, using anti-Rab3IP (Cell Signaling Technology/CST, USA), anti-LC3 (CST, USA), anti-p62 (CST, USA), and anti-GAPDH (CST, USA) antibodies. GAPDH was used as the loading control.

Immunohistochemistry (IHC)
--------------------------

Standard two-step IHC was applied to investigate the expression of proteins in human GC tissue. Primary antibodies against Rab3IP (1:100) were incubated with the sections overnight at 4 ºC and Mayer\'s haematoxylin was used for nuclear counter staining. Slides were reviewed and evaluated by two blinded pathologists and the intensity of staining of the cancer cells was scored according to the standard stage as follows: 0 (negative, no staining), 1 (weak, light yellow), 2 (moderate, yellow brown), and 3 (intense, brown). High expression (or overexpression) was defined as an intensity score of ≥ 2, and a score of \< 2 indicated low expression.

Cell counting kit 8 (CCK-8) assay
---------------------------------

AGS and MKN45 cells were seeded into 96-well plates at a density of 3,000 cells per well and cultured for 24 h in RPMI Medium 1640 plus 10% FBS at 37 ºC and 5% CO~2~. RPMI 1640 in wells without cells served as blank control. Cells were quantified after 48 h using the CCK-8 assay (Donjindo, Kumamoto, Japan) and a microplate reader. The absorbance data (OD value) at 450 nm were collected for cell viability analysis.

Cell apoptosis assay
--------------------

AGS and MKN45 were seeded into 6-well plates at a density of 1 × 10^6^ cells per well and cultured for 24 h. Then the cells were washed with PBS three times, trypsinised, and harvested for staining using an annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis kit (Keygen, Nanjing, China). The staining of cells was assessed by flow cytometry and data analysed using the FlowJo software, with FITC-positive cells considered apoptotic.

Plate clone formation assay
---------------------------

For plate colony formation assays, AGS and MKN45 cells were seeded at a density of 500 cells/dish and incubated at 37 ºC, 5% CO~2~ for 1 week, and fresh medium was replenished as needed. The cell culture was terminated once visible clones appeared. The cell clones were washed with PBS, fixed for 15 minutes and stained with Giemsa. The number of stained clones was then counted and analysed.

Confocal laser scanning microscopy (CLSM)
-----------------------------------------

AGS and MKN45 cells were transfected with LC3 double-fluorescent autophagy virus, and positive transformants selected in the presence of puromycin. Following this, the cells were cultured in RPMI 1640 with or without treatment with 3-methyladenine (3-MA, MedChemExpress, Shanghai China), rapamycin (RAPA, MedChemExpress, Shanghai China), or miR-532-3p. After cell adhesion was achieved, the culture medium was replaced as described above. At the time indicated, the cells were fixed with 4% paraformaldehyde, washed, then the cell nuclei were mounted with DAPI at 37 ºC for 20 min. Fluorescence measurements were performed using an FV10i confocal microscope (Olympus, Tokyo, Japan).

Dual-luciferase reporter assay
------------------------------

MKN45 cells were seeded into a 96-well plate. Forty-eight hours after being co-transfected with pmirGLO-WT-Rab3IP-3ʹUTR (wild type) or pmirGLO-MT-Rab3IP-3ʹUTR (mutant type) plasmid along with gga-miR-532-3p mimic, firefly and Renilla luciferase activities were measured using a Dual-GLO Luciferase Assay System Kit (Promega, USA) according to the manufacturer\'s instructions. Luminescence was measured using a Fluorescence/ Multi-Detection Microplate Reader (BioTek, USA) and firefly luciferase activities were normalised to Renilla luminescence in each well.

*In vivo* cell proliferation assay
----------------------------------

Male Sprague-Dawley rats aged 6 to 8 weeks were purchased from the Experimental Animal Center of Southern Medical University, which is certified by the Guangdong Provincial Bureau of Science. The rats were raised in a clean environment, and all animal experiments were performed according to ethical practices. To establish the xenograft model, 5 × 10^6^ cells in 0.2 mL of serum-free DMEM were injected subcutaneously into the right flank of nude mice. miR-532-3p agomir (GenePharma Company, Shanghai, China) was dissolved in PBS and injected into the tumour after the injection of cancer cell and the mice were killed 2 weeks later. The tumours were surgically removed from the mice and weighed.

Statistical analyses
--------------------

We used SPSS statistical package version 19.0 for Windows (SPSS, Chicago, IL, USA) and GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA) for statistical analysis. We used Mann-Whitney test to compare the mRNA levels of *RAB3IP* and miR-532-3p between GC tissues and normal tissues. The relationship between Rab3IP and miR-532-3p was assessed by linear regression analysis. Comparison among multiple groups was made using one-way ANOVA. P \<0.05 was considered to indicate a statistically significant difference.

Results
=======

Rab3IP is upregulated in GC
---------------------------

qRT-PCR, western blotting, and IHC were utilised to clarify the expression pattern of Rab3IP in GC. From the results of qRT-PCR, *RAB3IP* transcript levels were found to increase in GC samples compared with those in normal gastric mucosa samples (**Fig [1](#F1){ref-type="fig"}A**). Consistently, Rab3IP showed a higher expression in GC samples at the protein level (**Fig [1](#F1){ref-type="fig"}B**). To further characterise Rab3IP expression in GC, tissue microarray (TMA) containing 150 samples of GC was used for IHC analysis; here, 67.3% (101 / 150) of the samples were classified as Rab3IP-positive (**Fig [1](#F1){ref-type="fig"}D**). Furthermore, we analysed the relationship between the expression of Rab3IP with the relative clinical parameters. Rab3IP\'s clinical pathology value was further studied using Rab3IP expression in 150 cases of GC (**Table [1](#T1){ref-type="table"}**). The chi-square test results showed that the expression level of Rab3IP significantly correlated with tumour size, differentiation, tumour (T) stage, lymph node (N) stage, and serum CEA and CA-724 levels. However, analysis of CA-199 serum levels, lymphatic invasion, perineural infiltration, vascular invasion, and M staging were excluded. Among all the gastric cell lines, GES-1 cells showed least expression of Rab3IP. Furthermore, AGS cells showed the highest expression compared to other GC cell lines, while the expression in MKN 45 cells was relatively lower **(Fig [1](#F1){ref-type="fig"}C)**.

Depletion of Rab3IP reduces proliferation of GC cells
-----------------------------------------------------

The observation that overexpression of Rab3IP was correlated with tumour size and T stage further inspired us to examine the functional role of Rab3IP in GC cell lines. To investigate the effects of Rab3IP on the proliferation of GC cells, lentivirus-mediated knockdown of Rab3IP was employed in the AGS cells, as the expression was relatively higher in AGS cells based on western blotting results (**Fig [1](#F1){ref-type="fig"}C)**. The qRT-PCR results showed that lentivirus targeting Rab3IP efficiently reduced the mRNA expression of *RAB3IP* in AGS cells (**Fig [2](#F2){ref-type="fig"}A**). Owing to the reduction in Rab3IP levels, AGS-Rab3IP (-) cells showed lower OD value in the CCK-8 assay**(Fig [2](#F2){ref-type="fig"}B)**, fewer cell colonies in the plate clone formation assay (**Fig [2](#F2){ref-type="fig"}C**), and a 2-fold higher apoptotic rate in flow cytometry (**Fig [2](#F2){ref-type="fig"}D**), compared to the AGS-Rab3IP (-)-NC control group. In addition, elimination of Rab3IP significantly suppressed the tumorigenicity of AGS cells *in vivo*, as AGS-Rab3IP (-) cells exhibited less tumour mass and volume compared to the AGS-Rab3IP (-)-NC control group (**Fig [2](#F2){ref-type="fig"}E**).

Upregulation of Rab3IP enhances proliferation of GC cells
---------------------------------------------------------

Rab3IP was overexpressed in MKN45 cells using a lentivirus system, since the expression was relatively lower in MKN45 cells based on western blotting results (**Fig [1](#F1){ref-type="fig"}D**). After the transfection of Rab3IP plasmid, the MKN45-Rab3IP (+) group showed higher expression of *RAB3IP* transcripts (60-fold higher) compared to the control group (**Fig [3](#F3){ref-type="fig"}A**). Owing to the upregulation of Rab3IP, MKN45-Rab3IP (+) cells showed higher OD value in the CCK-8 assay**(Fig [3](#F3){ref-type="fig"}B)**, more cell colonies in the plate clone formation assay (**Fig [3](#F3){ref-type="fig"}C**), and a lower apoptotic rate in flow cytometry (**Fig [3](#F3){ref-type="fig"}D**), compared to the MKN45-Rab3IP (+)-NC control group. Furthermore, overexpression of Rab3IP dramatically promoted cell proliferation *in vivo*, as MKN45-Rab3IP (+) cells exhibited greater tumour mass and volume (**Fig [3](#F3){ref-type="fig"}E**).

Rab3IP inhibits autophagy of GC cells
-------------------------------------

Cell autophagy has been increasingly recognised to be associated with cell proliferation in GC[@B15]. To identify whether Rab3IP regulates cell proliferation in GC owing to its involvement in the process of cell autophagy, we investigated the effect of Rab3IP on autophagy-related markers. The CCK-8 results revealed that depletion of Rab3IP significantly reduced the proliferation ability of AGS cells, but this was reversed in the presence of 3-MA, a classic cell autophagy inhibitor (**Fig [4](#F4){ref-type="fig"}A)**. On the contrary, enhanced cell proliferation induced by overexpression of Rab3IP was suppressed in the presence of RAPA, a classic cell autophagy inducer (**Fig [4](#F4){ref-type="fig"}B)**. Confocal laser scanning microscopy (CLSM) showed that depletion of Rab3IP led to more autophagosomes, while upregulation of Rab3IP led to fewer autophagosomes; however, these phenomena could be reversed by the addition of 3-MA and RAPA, respectively (**Fig [4](#F4){ref-type="fig"}C** and**Fig [4](#F4){ref-type="fig"}D**). To ascertain whether expression of Rab3IP is associated with autophagy, western blotting was used to detect autophagy-related markers (**Fig [4](#F4){ref-type="fig"}E**). We observed an increase in the intensity of both the LC3-II and p62 bands in the AGS-Rab3IP (-) group having lower expression of Rab3IP compared with that in the negative control group. However, this increase was again restrained by the addition of 3-MA. Furthermore, MKN45-Rab3IP (+) cells that overexpressed Rab3IP exhibited a decrease in the intensity of both LC3-II and p62 bands, which was reversed by the addition of RAPA.

Rab3IP is a direct target of miR-532-3p in GC
---------------------------------------------

To further explore the upstream regulatory pathway of Rab3IP in GC, we utilised publicly available bioinformatic algorithms (TargetScan and miRMALK) to predict its upstream microRNAs. The results predicted five miRNAs (miR-450-5p, miR-217, miR-532-3p, miR-935, and miR-584-5p) as potential regulators targeting Rab3IP in GC. Of these, the transfection of miR-532-3p mimic showed the most significant reduction in Rab3IP expression, both at the protein (**Fig [5](#F5){ref-type="fig"}A**) and mRNA levels (**Fig [5](#F5){ref-type="fig"}B**), compared to the control and other four miRNAs. Luciferase reporter assay was performed to further corroborate this finding, A significant decrease in luciferase activity of the wild type vector was observed, whereas mutation in the putative binding site in the 3ʹUTR region of *RAB3IP* abrogated the suppressive ability of miR-532-3p, verifying that miR-532-3p regulates endogenous *RAB3IP* by directly binding to its 3ʹUTR region in GC cells (**Fig [5](#F5){ref-type="fig"}C**). To further measure the original expression level of miR-532-3p in GC, qRT-PCR analysis was performed using 40 paired GC samples. Simultaneously, the mRNA levels of *RAB3IP* were determined to verify its correlation with miR-532-3p. Consistent with the bioinformatics prediction, the expression of miR-532-3p was negatively correlated with Rab3IP expression (*r*=-0.4761, *p=*0.0019) (**Fig [5](#F5){ref-type="fig"}D**). Moreover, miR-532-3p was downregulated in 77.5% (31/40) of the GC samples (**Fig [5](#F5){ref-type="fig"}E),** while Rab3IP was upregulated in 75% (30/40) of the samples (**Fig [1](#F1){ref-type="fig"}A**).

Rab3IP upregulation enhances proliferation of GC cells, which is reversed by miR-532-3p
---------------------------------------------------------------------------------------

Based on the observation that the expression levels of miR-532-3p and Rab3IP are negatively correlated, their functional link was further explored. Since Rab3IP was previously demonstrated to enhance the proliferation of GC cells through inhibition of cell autophagy, we determined whether miR-532-3p could reverse this enhancing capacity. As expected, the enhanced cell proliferation induced by overexpression of Rab3IP was suppressed by the addition of miR-532-3p in the CCK-8 assay (**Fig [6](#F6){ref-type="fig"}A**). Apoptosis assay was used to determine the function of miR-532-3p, as significant alteration induced by miR-532-3p was observed compared to that in the MKN45-Rab3IP (+) group (**Fig [6](#F6){ref-type="fig"}B**). To verify the effect of miR-532-3p on tumorigenesis*in vivo*, GC cells were implanted subcutaneously into nude mice and miR-532-3p showed its potential in decreasing the tumour burden and slowing down the tumour growth rate (**Fig [6](#F6){ref-type="fig"}C**). Furthermore, we used CLSM to observe the indicated cells and found that miR-532-3p could induce more autophagosomes (**Fig [6](#F6){ref-type="fig"}D**). Consistent with the CLSM results, decrease in the intensity of both the LC3-II and p62 bands was observed in the MKN45-Rab3IP (+) group having higher expression of Rab3IP compared with the negative control group, and this decreased expression could be reversed by miR-532-3p (**Fig [6](#F6){ref-type="fig"}E**).

Discussion
==========

Several studies have shown that the expression of GTPase proteins is abnormal in many tumours, such as breast cancer, lung cancer, GC, and prostate cancer[@B16]-[@B19]. A novel molecular classification of GC has been put forward, which includes four subtypes: 1. EB virus positive, 2. Microsatellite instability (MSI) type, 3. Genome-stabilised (GS) type, 4. Chromosomal instability (CIN) type. The RHOA gene mutation or the RHO family GTPase activating protein gene fusion phenomenon is more common in the GS type[@B20]. Moreover, GTPases are widely involved in the signal pathway of cell proliferation and differentiation, which might have a huge impact on the development of cancer.

Rab3IP is one of the Rab family GTPase-activating proteins, which is known to be involved in intracellular vesicular trafficking and cytoskeleton regulation. Recent research concerning about the biological function of Rah3IP(Rabin8), has illustrated that the guanine nucleotide exchange reaction of Rab8 Protein was catalyzed by guanine nucleotide exchange factor Rabin8. According to the biophysical and structural details shown, mechanism of GDP displacement in the Rab8/Rabin8 system could be described as a disturbance of the structure of the nucleotide-binding regions of Rab8, in particular switch I and switch II. In addition, Rabin8 was identified as the specific GEF for Rab8 and affects the GTP/GDP exchange[@B21], [@B22].Rab3IP has been reported to be closely related to the occurrence, development, and metastasis of colorectal cancer, salivary gland cancer, and cervical cancer[@B9], [@B23]. In our previous study, we also found that, Rab3IP is upregulated in both gastric cancer cell lines and human tissues, and interacts with SSX2. Furthermore, we also revealed the involvement of Rab3IP and SSX2 in the epithelial-mesenchymal transition (EMT) and their potential implication in the invasion and metastasis of gastric cancer[@B10]. However, the specific mechanism of action of Rab3IP during the proliferation of GC cells have not been fully elucidated. Our study demonstrated that Rab3IP is upregulated in GC tissues. The expression level of Rab3IP was found to be highly correlated with tumour size, differentiation degree, tumour (T) stage, lymph node (N) stage, and serum CEA and CA-724 levels. To explore the biological function of Rab3IP in GC, we depleted Rab3IP in AGS cells. This caused the *in vitro* proliferative capacity of AGS cells to be significantly inhibited, while apoptosis increased. Consistently, the tumour volume and quality in AGS-transfected nude mice were significantly reduced. On the other hand, the overexpression of Rab3IP in MKN45 cells caused enhanced cell growth rate both*in vitro* and *in vivo*. As observed in GC, Rab3IP was found to be overexpressed in gliomas[@B7]. The authors used a 12q13-21 amplicon-specific genomic microarray and a bioinformatics amplification prediction tool, which showed that Rab3IP was one of the overexpressed genes in the amplified region, thereby confirming that Rab3IP is related to the proliferation of gliomas at the gene level. These results suggested that Rab3IP could promote tumour cell proliferation in GC. According to recent advancement in the molecular function of Rab3IP, it was proved to interact with SSX2, Rab8 and other proteins as an activator of GTP/GDP exchange. Thus, we hypothesis that it plays an important role in progress of gastric cancer. In addition, Rab proteins may affects the actions of Rab3IP. However, due to the limitation of the current study, we have not found the direct relation between Rab3IP biological function and the Rab3IP-Rab8 interaction[@B21], [@B22].

Autophagy is a highly conserved lysosome-dependent catabolic pathway in eukaryotes. It is closely related to various physiological and pathological processes and plays an important role in the development of tumours. The mTOR signalling pathway is a classical autophagy signalling pathway. Studies have shown that GTPases are involved in the mTOR signalling pathway and regulate autophagy in cancer cells[@B24]. Many Rab proteins, such as Rab1, Rab5, Rab7, Rab9A, Rab11, Rab23, Rab32, Rab33B, and Rab37, are involved in autophagy[@B25]-[@B27]. Rabl3 has been shown to be involved in the inhibition of autophagosome formation in lung cancer cells[@B28]. Furthermore, downregulation of Rab25 and Rab7 can promote autophagy of ovarian cancer cells[@B29], [@B30]. Therefore, we speculated that Rab3IP might promote the proliferation and differentiation of GC cells by affecting autophagy. We thus transfected AGS-Rab3IP (-) cells, MKN45-Rab3IP (+) cells, and their negative controls with LC3 double-fluorescing autophagic virus and observed them using CLSM.

The results showed that depletion of Rab3IP led to more autophagosomes, while upregulation of Rab3IP led to fewer autophagosomes; these effects were reversed by the addition of an autophagy inhibitor (3-MA) and enhancer (RAPA), respectively. To further corroborate the correlation of Rab3IP expression with autophagy, we used western blotting to detect autophagy-related markers and observed a similar trend. Autophagy can promote cell proliferation as a physiological process in normal cells. However, autophagy has been shown to inhibit proliferation in cancer cells like bladder cancer cells and breast cancer cells[@B31], [@B32]. In our study, upregulation of Rab3IP significantly promoted cell proliferation. Considering that it also led to the reduction of the number of autophagosomes, we concluded that the effect of Rab3IP on the proliferation of GC cells is mediated through regulation of autophagy.

There is increasing evidence that miRNAs play an important role in several key biological processes of GC and its pathogenesis. miRNAs are important inhibitors of oncogenes, such as Rab40b, Rab40c, Rab18, Rab22A, and other Rab family members, in various cancers[@B33]-[@B36]. Here, we found that miR-532-3p can directly target Rab3IP and that its expression is closely related to the expression level of Rab3IP in GC tissues. Earlier studies have found that miR-532-3p, a tumour suppressor, targets cancer cells by inducing new oncogenes, such as KRAS, MKL2, WNT9A, CSNK2A2, CHD4, and SH3PXD2A, in ovarian and lung adenocarcinoma[@B37]-[@B40]. Here, we demonstrate that miR-532-3p is downregulated in GC and exerts its biological function by targeting Rab3IP. We verified the low expression levels of miR-532-3p in GC tissues and demonstrated that miR-532-3p could reverse Rab3IP\'s promotion of proliferation in GC cells. Subsequently, we studied the biological function of miR-532-3p in GC cells and nude mice. The results showed that miR-532-3p can induce the production of more autophagosomes and reduce the tumour burden in nude mice. In addition, the expression of Rab3IP and miR-532-3p was linearly correlated in GC cells, confirming that the regulation of Rab3IP by miR-532-3p plays an important role in the development of GC.

Conclusion
==========

In summary, this study clarifies the essential link between miR-532-3p and Rab3IP in regulating the proliferation ability and their involvement in the autophagy process in human GC cells. Taking this into consideration, Rab3IP could serve as a potential target for the treatment of GC. However, the present study has some limitations. Firstly, the mechanism of how Rab3IP regulates cell proliferation through autophagy remains unclear. In addition, how miR-532-5p regulates cell proliferation in GC through the Rab3IP/autophagy pathway requires further exploration.
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![Rab3IP is overexpressed in gastric cancer (GC).**A.** Expression of *Rab3IP* transcripts in paired GC tissues and peritumoral normal tissues. **B.** Western blot analysis of Rab3IP in paired GC tissues and peritumoral normal tissues. **C.** Western blot analysis of Rab3IP in GC cell lines. **D.** Tissue microarray (TMA) analysis of Rab3IP in primary human GC tissues. \*\* means *P\<*0.001. Scar bar, 100 nm.](jcav09p4363g001){#F1}

![Depletion of Rab3IP suppresses cell proliferation in gastric cancer. **A.** Quantitative real-time-PCR analysis to confirm knock-down efficiency of Rab3IP transcripts in AGS cells. **B.** CCK-8 assay using AGS-Rab3IP (-) and AGS- Rab3IP (-)-NC cells. **C.** Clone formation assay using AGS-Rab3IP (-) and AGS- Rab3IP (-)-NC cells. **D.** Apoptosis rates of AGS-Rab3IP (-) and AGS- Rab3IP (-)-NC cells using Annexin V-FITC/PI kit. **E.** Tumour xenograft model established by subcutaneous injection in nude mice (n = 3). Data points are presented as mean tumour weight (gram) and tumour volume (mm^3^). \*means *P\<*0.05, \*\* means *P\<*0.01, \*\*\* means *P\<*0.001.](jcav09p4363g002){#F2}

![Overexpression of Rab3IP promotes cell proliferation in gastric cancer. **A.** Quantitative real-time-PCR analysis to show overexpression of Rab3IP transcripts in MKN45 cells. **B.** CCK-8 assay using MKN45-Rab3IP (+) and MKN45- Rab3IP (+)-NC cells. **C.** Clone formation assay using MKN45-Rab3IP (+) and MKN45- Rab3IP (+)-NC cells. **D.** Apoptosis rates of MKN45-Rab3IP (+) and MKN45- Rab3IP (+)-NC cells using Annexin V-FITC/PI kit. **E.** Tumour xenograft model established by subcutaneous injection in nude mice (n = 3). Data points are presented as mean tumour weight (gram) and tumour volume (mm^3^). \*means *P\<*0.05, \*\* means *P\<*0.01, \*\*\* means *P\<*0.001.](jcav09p4363g003){#F3}

![Rab3IP promotes cell autophagy in gastric cancer**. A.** Effect of downregulation of *Rab3IP* and addition of 3-methyladenine (3-MA) on cell proliferation using CCK-8 assay. **B** Effect of overexpression of *Rab3IP* and addition of RAPA on cell proliferation using CCK-8 assay. **C** LC3 fluorescence in AGS cells after downregulation of *Rab3IP* and addition of 3-MA. **D** LC-3 fluorescence in MKN45 cells after overexpression of *Rab3IP* and addition of RAPA.**E** Western blot analysis of Rab3IP, LC3-I, LC3-II, p62, and GAPDH in AGS and MKN45 cells. \*\*\* means *P\<*0.001. Scale bar, 50 nm.](jcav09p4363g004){#F4}

![Rab3IP is a direct target of miR-532-3p in gastric cancer (GC).**A.** Western blot analysis of Rab3IP in the indicated cells treated with different mimics. **B.** Expression analysis of *Rab3IP* in the indicated cells treated with different mimics. **C.** Luciferase assay revealed that miR-532-3p directly binds to the 3ʹUTR region of *Rab3IP*. **D.** Correlation between miR-532-3p and *Rab3IP* at mRNA level in 40 paired human gastric cancer tissues and adjacent normal mucosa tissues. **E.** Upregulation of miR-532-3p was found in (31/40) 77.5% of GC cases. Data represents the log2 ratio of miR-532-3p level in GC tissues compared to the corresponding non-tumour tissues. **F.** The expression of miR-532-3p in GC tumour (T) versus non-tumour (NT) tissues, as detected by qRT-PCR. \*means *P\<*0.05.](jcav09p4363g005){#F5}

![Enhanced cell proliferation induced by Rab3IP is restrained by miR-532-3p in gastric cancer. **A.** Effect of overexpression of miR-532-3p and Rab3IP on cell proliferation using CCK-8 assay. **B.** Effect of overexpression of Rab3IP and addition of miR-532-3p on cell apoptosis using Annexin V-FITC/PI assay. **C.** Tumour xenograft model established by injecting Rab3IP-overexpressed MKN45 cells, while miR-532-3p agomir, a small molecule inhibitor, was injected into the tumour (n = 3). Data points are presented as mean tumour weight (gram) and tumour volume (mm^3^). **D.** LC-3 fluorescence in MKN45 after introduction of Rab3IP and addition of miR-532-3p. **E.** Western blot analysis of Rab3IP, LC3-I, LC3-II, p62, and GAPDH in MKN45 cells after introduction of Rab3IP and addition of miR-532-3p. \*means *P\<*0.05, \*\* means *P\<*0.01, \*\*\* means *P\<*0.001. Scar bar, 50 nm.](jcav09p4363g006){#F6}

###### 

Correlation between Rab3IP protein expression and the clinicopathological parameters.

  Variables                      Cases, n   Rab3IP protein expression   *P* value   
  ------------------------------ ---------- --------------------------- ----------- -------
  **Gender**                                                                        
  Male                           105        36                          69          0.573
  Female                         45         13                          32          
  **Age at diagnosis (years)**                                                      
  \<60                           92         25                          67          0.077
  ≥60                            58         24                          34          
  **BMI**                                                                           
  \<25                           116        42                          74          0.100
  ≥25                            34         7                           27          
  **Abdominal surgery**                                                             
  Yes                            130        42                          88          0.802
  No                             20         7                           13          
  **Comorbidity**                                                                   
  Yes                            102        35                          67          0.580
  No                             48         14                          34          
  **Complication**                                                                  
  Yes                            59         17                          42          0.478
  No                             91         32                          59          
  **CA-199**                                                                        
  ≤37                            120        42                          78          0.279
  \>37                           30         7                           23          
  **CEA**                                                                           
  ≤5                             116        43                          73          0.038
  \>5                            34         6                           28          
  **CA-125**                                                                        
  ≤6                             99         38                          61          0.044
  \>6                            51         11                          40          
  **Size (diameter, cm)**                                                           
  \<3                            38         19                          19          0.015
  ≥3                             112        30                          82          
  **Differentiation Degree**                                                        
  Well and medium                43         20                          23          0.033
  Poorly and undifferentiated    107        29                          78          
  **Lymphatic invasion**                                                            
  Yes                            81         30                          51          0.227
  No                             69         19                          50          
  **Nerve invasion**                                                                
  Yes                            47         18                          29          0.351
  No                             103        31                          72          
  **Vascular invasion**                                                             
  Yes                            91         33                          58          0.287
  No                             58         16                          43          
  **T stage**                                                                       
  1 and 2                        38         19                          19          0.015
  3 and 4                        112        30                          82          
  **N stage**                                                                       
  0                              47         24                          23          0.002
  1 and 2                        103        25                          78          
  **M stage**                                                                       
  M0                             128        43                          85          0.631
  M1                             22         6                           16          
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